Table 2.
The Association of SIRI, NLR, and PLR with Clinicopathologic Characteristics in 245 Patients with Advanced Lung Adenocarcinoma
| Characteristics | SIRI <0.71 | SIRI ≥0.71 | P | NLR <3.36 | NLR ≥3.36 | P | PLR <167.01 | PLR ≥167.01 | P |
|---|---|---|---|---|---|---|---|---|---|
| Age | |||||||||
| <65 | 41(16.7%) | 136(55.5%) | 0.606 | 102(41.6%) | 75(30.6%) | 0.251 | 87(35.5%) | 90(36.7%) | 0.669 |
| ≥65 | 13(5.3%) | 55(22.4%) | 33(13.5%) | 35(14.3%) | 36(14.7%) | 32(13.1%) | |||
| Gender | |||||||||
| Female | 42(17.1%) | 96(39.2%) | <0.001 | 85(34.7%) | 53(21.6%) | 0.028 | 68(27.8%) | 70(28.6%) | 0.797 |
| Male | 12(4.9%) | 95(38.8%) | 50(20.4%) | 57(23.3%) | 55(22.4%) | 52(21.2%) | |||
| Smoking status | |||||||||
| No | 47(19.2%) | 129(52.7%) | 0.006 | 98(40.0%) | 78(31.8%) | 0.777 | 83(33.9%) | 93(38.0%) | 0.156 |
| Yes | 7(2.9%) | 62(25.3%) | 37(15.1%) | 32(13.1%) | 40(16.3%) | 29(11.8%) | |||
| ECOG PS | |||||||||
| 0–1 | 50(20.4%) | 154(62.9%) | 0.039 | 121(49.4%) | 83(33.9%) | 0.004 | 111(45.3%) | 93(38.0%) | 0.004 |
| 2 | 4(1.6%) | 37(15.1%) | 14(5.7%) | 27(11.0%) | 12(4.9%) | 29(11.8%) | |||
| Brain metastasis | |||||||||
| No | 47(19.2%) | 172(70.2%) | 0.616 | 122(49.8%) | 97(39.6%) | 0.678 | 110(44.9%) | 109(44.5%) | 1.000 |
| Yes | 7(2.9%) | 19(7.8%) | 13(5.3%) | 13(5.3%) | 13(5.3%) | 13(5.3%) | |||
| EGFR mutation | |||||||||
| 19-DEL | 27(11.0%) | 107(43.7%) | 0.001 | 70(28.6%) | 64(26.1%) | 0.014 | 63(25.7%) | 71(29.0%) | 0.125 |
| L858R | 20(8.2%) | 81(33.1%) | 55(22.4%) | 46(18.8%) | 52(21.2%) | 49(20.0%) | |||
| Other | 7(2.9%) | 3(1.2%) | 10(4.1%) | 0(0%) | 8(3.3%) | 2(0.8%) |
Abbreviations: ECOG PS, Eastern Cooperative Oncology Group performance status; SIRI, systemic immune response index; NLR, neutrophil to lymphocyte ratio; PLR, platelet to lymphocyte ratio.